Navigation Links
CAPS Provides Input on Draft Sterile Compounding Legislation
Date:5/3/2013

BETHLEHEM, Pa., May 3, 2013 /PRNewswire/ -- Supporting consistent federal oversight of sterile compounding in the United States, Central Admixture Pharmacy Services, Inc. (CAPS®), a B. Braun company, submitted its comments today to the U.S. Senate Committee on Health, Education, Labor, and Pensions (HELP) regarding the committee's draft legislation on sterile compounding.

"We strongly believe that consistency will be the key," said Mike Koch , CAPS Vice President, Marketing and Support Services. "To help ensure both patient safety and confidence in the nation's drug supply, it's important to hold all compounded sterile preparations made in the U.S. to a consistent set of quality standards, while avoiding potentially dangerous loopholes."

CAPS delivers compounded sterile preparations daily, both locally and nationwide, from 25 locations. Included in the comments submitted to the Committee was support for the newly proposed "Compounding Manufacturer" category. CAPS looks forward to further engaging in the dialogue on this important patient safety legislation.

About CAPS

CAPS®, the nation's largest network of outsourcing admixture pharmacies, was pioneered in 1991 to deliver high-quality admixture services and solutions to a dynamic and challenging pharmacy environment. State-licensed and FDA-registered, CAPS pharmacies operate 365 days a year to dispense labeled, patient-specific and anticipatory IV prescriptions. To learn more about CAPS, visit www.capspharmacy.com.

About B. Braun

B. Braun Medical Inc. (B.Braun), a leader in infusion therapy and pain management, develops, manufactures, and markets innovative medical products and services to the healthcare industry. The Company is committed to eliminating preventable treatment errors and enhancing patient, clinician and environmental safety. Guided by its "Sharing Expertise®" philosophy, B.Braun continuously exchanges knowledge with customers, partners and clinicians to address the critical issues of improving care and lowering costs.

The B.Braun Group of Companies in the U.S. includes B.Braun, Aesculap® and CAPS®. B.Braun's U.S. headquarters is located in Bethlehem, Pennsylvania. The B.Braun Group of Companies employs more than 46,000 employees in more than 50 countries throughout the world. To learn more about B.Braun visit www.BBraunUSA.com.


'/>"/>
SOURCE Central Admixture Pharmacy Services, Inc. (CAPS®), a B. Braun company
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Valeant Pharmaceuticals Provides Efinconazole Update
2. Arena Pharmaceuticals Provides Corporate Update and Reports First Quarter 2013 Financial Results
3. OncoGenex Pharmaceuticals, Inc. Provides Clinical Development Program Overview and Reports Financial Results for First Quarter 2013
4. Haemonetics Reports 4th Quarter Fiscal 2013 Revenue Up 34% and Adjusted EPS of $0.48; Fourth Quarter and Full Year Organic Revenue Up 4% and Full Year Adjusted EPS of $1.71; Completes Hemerus Medical, LLC Acquisition and Provides Fiscal 2014 Guidanc
5. DietBrandReviews.com Provides a Comprehensive Review of the Dukan Diet
6. Hill-Rom Reports Fiscal Second Quarter Adjusted Earnings Per Share In Line With Expectations; Provides Third Quarter And Updated Full-Year Financial Outlook
7. Medical Alarm Concepts Files Information Statement and Provides Update on Corporate Activity
8. Hand-Held Device Provides Lab-Quality Troponin Test Results in 15 Minutes to Identify Patients Suspected of Heart Attack
9. Accuray Provides Clarification on Recently Initiated Voluntary Recalls
10. Centers for Specialty Care Group Provides On-Site Dialysis at Many of Its NYC Rehab Centers
11. DocuTrac, Inc. Provides Cloud Hosted Solution for Behavioral Health Providers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/8/2017)... , June 8, 2017  Less than a month ... more than 200,000 companies, including hospital networks, in over ... as one of the largest online extortion attempts ever ... healthcare market, it is imperative that providers understand where ... data from this — and many other very real ...
(Date:6/7/2017)... 2017  Novavax, Inc., (Nasdaq: NVAX ) today ... trials of its RSV F protein recombinant nanoparticle vaccine candidate ... been published in the journal Vaccine ... prior scientific conferences). The Company previously announced top line ... developing the RSV F Vaccine with the goal of protecting ...
(Date:6/3/2017)... , June 3, 2017  Eli Lilly and ... that results from the Phase 3 MONARCH 2 ... & 6 inhibitor, in combination with fulvestrant, significantly ... fulvestrant alone in women with hormone-receptor-positive (HR+), human ... cancer who have relapsed or progressed after endocrine ...
Breaking Medicine Technology:
(Date:6/23/2017)... ... ... Studies show evidence that carotenoids and antioxidants derived either from the diet or from ... how often do ophthalmologists and optometrists in Sweden recommend the use of nutritional supplements, ... symptoms of AMD? A study published recently in Dove Medical Press journal, ...
(Date:6/23/2017)... ... June 23, 2017 , ... Dr. Ran ... York, has recently begun offering three new minimally invasive procedures to patients who ... and reducing downtime, Dr. Rubinstein is excited to bring microneedling, microneedling facials, and ...
(Date:6/23/2017)... ... June 23, 2017 , ... Everybody has their own ... others prefer to read it, and some people don't like it at all. FindaTopDoc ... what they found: , Erotic literature can give readers a taste of their deepest, ...
(Date:6/23/2017)... Beverly Hills, CA (PRWEB) , ... June 23, 2017 , ... ... deep plane facelift . Dr. Talei has come up with a proprietary technique ... wrinkles—it releases and lifts tissues that have dropped. For all ages, patients can expect ...
(Date:6/23/2017)... ... June 23, 2017 , ... ... Conference from Sept. 18 to 20. , The two-day conference is focused on ... the goal of improving patients’ lives and eliminating racial breast cancer-related disparities. The ...
Breaking Medicine News(10 mins):